SUMMARY
The degradation and release of cardiac myosin binding protein-C (cMyBP-C) upon cardiac damage may stimulate an inflammatory response and autoantibody (AAb) production. We determined whether the presence of cMyBP-C-AAbs associated with adverse cardiac function in cardiovascular disease patients. Importantly, cMyBP-C-AAbs were significantly detected in acute coronary syndrome patient sera upon arrival to the Upon myocardial damage, the release of previously "hidden" cardiac proteins into the circulation may trigger an immune response and the production of autoantibodies (AAbs) that target cardiac antigens (2) . Indeed, such AAbs have been critically linked to heart failure (2-4). The myocardial injury that occurs in patients with AMI may cause leakage of cardiac antigens into the circulation and the production of AAbs that associate with AMI severity (5) .
Cardiac myosin binding protein-C (cMyBP-C) is a sarcomeric regulatory protein that controls cardiac contractile function (1, 6, 7) . cMyBP-C contains 8 immunoglobulin-like domains, 3 fibronectin type III domains, a proline-alanine-rich region between C0 and C1, and an M domain (1) . Recently, it was demonstrated that cMyBP-C is extensively proteolyzed during AMI, and can be released into the circulation potentially serving as a biomarker of AMI (6, 8) . Interestingly, previous work has shown a strong reactivity and immunogenicity for AAbs against fragments of murine and human cMyBP-C that could generate experimental autoimmune myocarditis and dilated cardiomyopathy (DCM) in animal models (9) (10) (11) . However, a systematic largescale human study testing the antigenicity of human cMyBP-C domains in patients with AMI is necessary to determine the association of cMyBP-C-AAbs with clinical measurements of cardiac dysfunction and patient outcome.
In the present study, we used serum sam- HCM ¼ hypertrophic cardiomyopathy; OD ¼ optical density; other abbreviations as in Figure 1 .
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Lynch et al. Interestingly, an elevated percentage of patients who were negative for AAbs to these regions could also be classified as having STEMI than NSTEMI or UA.
However, a greater percentage of cMyBP-C-AAbnegative patients were classified as having NSTEMI than STEMI or UA when compared irrespective of the 
